Cross-Platform Gene Signature to Predict Survival Outcomes for Nasopharyngeal Carcinoma
JCO Precision Oncology · 2026-07 · 10 (7)
DOI: 10.1200/po-26-00029 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Precision Oncology, 2026-07. Verfasst von Huaping Li und 14 weiteren Autor:innen. Beteiligte Einrichtung: School of Biomedical Sciences, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China. Hauptthemen laut MEDLINE: Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Transcriptome. Die Arbeit nennt 33 Literaturangaben.
Abstract (Originalsprache)
PURPOSE Nasopharyngeal carcinoma (NPC) is a multifactorial malignancy often diagnosed at an advanced stage due to nonspecific early symptoms. Accurate prognostic stratification is essential for individualized therapy but remains challenging because of biological and clinical heterogeneity. This study aimed to develop and validate a gene expression–based prognostic signature for locally advanced NPC. METHODS This retrospective biomarker investigation combined transcriptomic profiling and survival analyses. A prognostic model was constructed using LASSO-Cox regression in the discovery cohort (N = 99) from the multicenter, randomized phase III trial NPC-0501, and validated in independent cohorts (N = 133) from Queen Elizabeth Hospital (QEH), Hong Kong, and Sun Yat-sen University Cancer Center (SYS), Guangzhou, using different profiling methods. Mechanisms underlying the signature were explored using single-cell RNA-seq (scRNA-seq) data. The primary outcome was 3-year progression-free survival (PFS), with 5-year overall survival (OS) as a secondary end point. Performance was evaluated using hazard ratios (HRs) and survival probabilities (SP). RESULTS A 5-gene signature ( SPP1 , IL18BP , PALMD , WDR35 , and SOCS6 ) predicted 3-year PFS in the NPC-0501 cohort (HR, 0.046 [95% CI, 0.011 to 0.190]; P < .001), separating high-risk from low-risk patients (SP, 42.9% v 96.0%; P < .0001). It predicted survival in both validation cohorts, with associations with 5-year OS in QEH (SP, 72.7% v 100%; P < .001) and 3-year PFS in SYS (SP, 70.5% v 93.2%; P = .0059). It outperformed a published metastasis-related model. Single-cell analyses showed SPP1 enrichment in M2 macrophages, linking high risk with an immunosuppressive tumor microenvironment. CONCLUSION A robust five-gene signature was established and validated for prognostic stratification of locally advanced NPC. Reproducibility across transcriptomic platforms and biological relevance support clinical application to guide personalized treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Biomedical Sciences, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
- Centre for Oncology and Immunology, Hong Kong Science Park, Hong Kong SAR, China.
- Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong SAR, China.
- Department of Pathology, Queen Elizabeth Hospital, Hong Kong SAR, China.
- Department of Clinical Oncology, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
- Department of Clinical Oncology, University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
ORCID-Profile: Kenneth Sik Kwan Chan, Suyu Hao, Kazi Anisha Islam, Wei Dai, Ka On Lam, Victor Ho Fun Lee, Roger Kai Cheong Ngan, Anne Wing Mui Lee, Jason Wing Hon Wong, Chi Leung Chiang
Zitieren
APA
Li, H., Jing, Q., Chow, J. C. H., Cheuk, W., Chan, K. S. K., Hao, S., Islam, K. A., Dai, W., Lam, K. O., Lee, V. H. F., Ng, W. T., Ngan, R. K. C., Lee, A. W. M., Wong, J. W. H., & Chiang, C. L. (2026). Cross-Platform Gene Signature to Predict Survival Outcomes for Nasopharyngeal Carcinoma. JCO Precision Oncology, 10(7). https://doi.org/10.1200/po-26-00029
Vancouver
Li H, Jing Q, Chow JCH, Cheuk W, Chan KSK, Hao S, et al. Cross-Platform Gene Signature to Predict Survival Outcomes for Nasopharyngeal Carcinoma. JCO Precision Oncology. 2026;10(7). doi:10.1200/po-26-00029
BibTeX
@article{Li2026,
author = {Li, Huaping and Jing, Qiuyu and Chow, James Chung Hang and Cheuk, Wah and Chan, Kenneth Sik Kwan and Hao, Suyu and Islam, Kazi Anisha and Dai, Wei and Lam, Ka On and Lee, Victor Ho Fun and Ng, Wai Tong and Ngan, Roger Kai Cheong and Lee, Anne Wing Mui and Wong, Jason Wing Hon and Chiang, Chi Leung},
title = {Cross-Platform Gene Signature to Predict Survival Outcomes for Nasopharyngeal Carcinoma},
journal = {JCO Precision Oncology},
year = {2026},
volume = {10},
number = {7},
doi = {10.1200/po-26-00029}
}
EUVIMED